Methods and compositions for treating diabetes
AssigneeGolden Biotechnology Corporation
InventorsSheng-Yung Liu, Wu-Che Wen
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for treating diabetes by cyclohexenone compounds.
Claims20
A method for treating diabetes comprising administering to a subject a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)mCH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
A method of inhibiting an increase in a blood sugar level in a subject, comprising administering to the subject affected by a disease resulting from hyperglycemia or glucose intolerance or abnormal glucose in need a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)mCH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
A method for treating or reducing the risk of a disease resulting from hyperglycemia or glucose intolerance or abnormal glucose of a subject, comprising administering to the subject affected by said disease in need a therapeutically effective amount of a compound having the structure:
- wherein each of X and Y independently is oxygen, NR5 or sulfur;
- R is a hydrogen or C(═O)C1-C8alkyl;
- each of R1, R2 and R3 independently is a hydrogen, methyl or (CH2)mCH3;
- R4 is NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, halogen, 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, glucosyl, wherein the 5 or 6-membered lactone, C1-C8alkyl, C2-C8alkenyl, C2-C8alkynyl, aryl, and glucosyl are optionally substituted with one or more substituents selected from NR5R6, OR5, OC(═O)R7, C(═O)OR5, C(═O)R5, C(═O)NR5R6, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, and C1-C8 haloalkyl;
- each of R5 and R6 is independently a hydrogen or C1-C8alkyl;
- R7 is a C1-C8alkyl, OR5 or NR5R6;
- m=1-12;
- and
- n=1-12;
- or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof.
Dependencies are inferred from the claim text.